Top IVIG Brands: Leading Choices for Intravenous Immunoglobulin Therapy

The world of Intravenous Immunoglobulin (IVIG) therapy is rich with numerous brands offering high-quality solutions for individuals with immune deficiencies. As patients and healthcare professionals seek reliable options, several manufacturers stand out due to their rigorous testing standards and consistent product availability. Among these are brands known for their innovative production processes and significant contributions to the field of immunotherapy. To help you navigate your options and choose the right IVIG product, we invite you to explore the top recommended brands below.

Illustration of ivig

Best brands of ivig in 2025

Octapharma

Octapharma is a leading producer of intravenous immunoglobulin (IVIG) products, notably with its Octagam(r) brand, which has been improving the lives of patients with immune disorders since its launch in 1995. Octagam(r) is available in two optimized concentrations, 5% and 10%, and is known for its high tolerability and efficacy across multiple indications, as demonstrated through various clinical studies. The product holds a significant market share, with Octagam accounting for 11.4% of the total grams sold in the U.S. IVIG market as of March 2018. The manufacturing process includes rigorous viral removal and inactivation steps, ensuring high safety standards. Octapharma's commitment to quality and safety has been recognized through multiple FDA approvals and successful inspections of its production sites.

CSL Behring

CSL Behring is a leading producer of immune globulin intravenous (IGIV) products, known for its strong market presence and innovative treatments. As of March 2018, CSL Behring's PrIGIVen held a significant market share of 21.6% in the IGIV market. The company's product, Hizentra, is the market share leader in the subcutaneous immunoglobulin (SCIg) market, holding more than 58% of the market share as of December 2023. CSL Behring's immunoglobulin sales have seen substantial growth, with a 21% increase in IG product sales to $4,675 million in the 2023 financial year. Their products, such as Privigen and Hizentra, are approved for various indications including Primary Immune Deficiency and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). For more information, visit CSL Behring's official website.

Grifols

Grifols is a leading producer of intravenous immunoglobulin (IVIG) products, known for its extensive scientific work and innovative production processes. In 2018, Grifols' Gamunex-C held a significant market share of 24.6% in the IVIG market, while Gammagard Liquid, another key product, led the market with a 26.2% share. The company has seen notable growth, with its immunoglobulin franchise increasing by 15.8% in 2023, driven by robust demand and favorable pricing. Grifols' subcutaneous immunoglobulin (SCIG) product, Xembify, also reported a significant growth of 37.3% in 2023. The company's commitment to developing next-generation Ig products further solidifies its position in the market.

Kedrion Biopharma

Kedrion Biopharma is a leading producer of intravenous immunoglobulin (IVIG) therapies, well-positioned to meet the growing demand in the U.S. IG market, which is expected to grow by roughly 9% per year over the next eight years. The company distributes some of the fastest-growing injectable IG therapies in the U.S. and has been selected by Biotest to distribute Yimmugo(r), a product produced at Biotest's state-of-the-art, FDA-certified facility in Germany. Kedrion's extensive experience and coverage in the immunoglobulin market make it a key player, with the U.S. IG market launch of Yimmugo(r) planned for Q1 2025. The global IVIG market, in which Kedrion is a major player, was valued at USD 11.98 billion in 2022 and is expected to grow at a CAGR of 7.3% from 2023 to 2030. Kedrion's product portfolio includes a wide array of treatments for rare and debilitating diseases, solidifying its position as a significant contributor to the IVIG market. For more detailed information on Kedrion's IVIG therapies, visit their website.

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a leading producer of intravenous immunoglobulin (IVIG) therapies, renowned for its commitment to innovation and patient care. With over 60 years of global heritage in plasma-based therapies, Takeda has established itself through products like GAMMAGARD LIQUID, which is approved for multiple neuromuscular disorder indications, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Takeda operates more than 100 state-of-the-art plasma donation centers through BioLife, ensuring high-quality plasma sourcing. The company's manufacturing process includes three dedicated viral inactivation and removal steps, enhancing safety margins against various viruses. Takeda's extensive portfolio and commitment to safety and quality have solidified its position in the global IVIG market.

Bio Products Laboratory

Bio Products Laboratory (BPL) is a prominent player in the intravenous immunoglobulin (IVIG) market, known for its high-quality products and significant contributions to the treatment of immunodeficiency diseases. The global IVIG market, which includes BPL's products, was valued at USD 11.98 billion in 2022 and is expected to grow at a CAGR of 7.3% from 2023 to 2030, driven by increasing demand for immunoglobulin replacement therapies and the rising prevalence of immunodeficiency diseases. In the U.S. market, which is a key segment for BPL, the IVIG market size was valued at USD 5.74 billion in 2022 and is projected to grow at a CAGR of 7.7% from 2023 to 2030. BPL's products are crucial in treating Primary Immunodeficiency Diseases (PIDD), with immunodeficiency diseases dominating the market with a revenue share of over 20.30% in 2022. The company's commitment to quality and innovation aligns with the growing healthcare expenditure and increasing FDA approvals in the sector.

Baxter International Inc.

Baxter International Inc. is a prominent player in the intravenous immunoglobulin (IVIG) market, although it has discontinued some of its IVIG products like Polygam S/D as of January 1, 2007. Despite this, the company's historical presence in the market is notable, with products like Polygam S/D holding a significant market share in the past, such as 12.5% of total grams sold between 2013 and 2018. The global IVIG market, in which Baxter participates, was estimated at USD 11.98 billion in 2022 and is expected to grow at a CAGR of 7.3% from 2023 to 2030. Baxter's overall healthcare portfolio includes a range of therapies, with its 2023 worldwide sales from continuing operations totaling $14.81 billion, indicating a strong presence in the healthcare sector. However, the company's current focus has shifted towards other segments like Medical Products and Therapies, and Pharmaceuticals. For more information on their operations, visit their official website.

LFB Group

The LFB Group is a prominent player in the intravenous immunoglobulin (IVIG) market, known for its high-quality products and significant market presence. In 2023, the hospital pharmacy segment, where LFB Group products are widely distributed, contributed more than 58% of the revenue share in the IVIG market. LFB Group, along with other key players like Grifols and CSL Behring, dominates the blood fractionation industry, influencing the cost and availability of plasma-derived products. The company's products are used to treat a range of immune and autoimmune diseases, contributing to the market's growth, which is expected to reach USD 34.92 billion by 2034 with a CAGR of 8.1%. The LFB Group's strong presence in North America and Europe further solidifies its position in the global IVIG market. For more information, visit their immunoglobulin product page.

Sanquin

Sanquin Plasma Products B.V. is a prominent player in the global intravenous immunoglobulin (IVIG) market, known for its high-quality products and significant market presence. The global IVIG market, which was valued at US$ 11.2 billion in 2021, is expected to grow at a CAGR of 7.3% from 2022 to 2031, with Sanquin being one of the key contributors to this growth. Sanquin's products are used to treat various autoimmune diseases and immunodeficiencies, driving the market's expansion. The company's commitment to innovation and quality ensures it remains a leader in the industry. As the market is projected to reach US$ 20.5 billion by 2031, Sanquin's role is anticipated to be pivotal.

Hualan Biological Engineering Inc.

Hualan Biological Engineering Inc. is a leading producer of intravenous immunoglobulin (IVIG), with a strong presence in the global market. The company reported significant sales growth, particularly in its plasma-derived therapeutics, including a 35% year-over-year increase in sales in the second quarter of 2018. Hualan's IVIG products are part of a market expected to reach USD 20.22 billion by 2030, growing at a CAGR of 6.9% driven by increasing demand for biologics and the prevalence of autoimmune diseases. The company's robust R&D capabilities and multiple products under development, including vaccines and monoclonal antibodies, further solidify its position in the industry. For a comprehensive financial overview, you can visit Hualan Biological Engineering Inc.'s financial details.